Supplementary Table 4. Subanalysis of septic and non-septic population

	Severe AKI ( <i>N</i> =19) in septic patients ( <i>N</i> =41)		Severe AKI ( <i>N</i> =8) in non-septic patients ( <i>N</i> =57)	
	Continuous NRI	IDI	Continuous NRI	IDI
Clinical Model				
+ NGAL	-9 (-68 to 51)	0.00 (-0.02 to 0.03)	56 (-17 to 128)	0.07 (-0.00 to 0.15)
+ IL-6	23 (-37 to 84)	0.01 (-0.02 to 0.03)	93 (40 to 147) <sup>a</sup>	0.05 (-0.07 to 0.16)
+ EPO	75 (18 to 131) <sup>a</sup>	0.12 (0.02 to 0.21) <sup>a</sup>	10 (-64 to 85)	0.00 (-0.03 to 0.04)
+ TIMP-2	103 (51 to 156) <sup>a</sup>	0.11 (0.00 to 0.21) <sup>a</sup>	-10 (-85 to 64)	0.00 (-0.04 to 0.05)
+ NAG	179 (151 to 207) <sup>a</sup>	0.30 (0.15 to 0.46) <sup>a</sup>	14 (-60 to 89)	0.06 (-0.04 to 0.16)

For continuous NRI and IDI, each model is made by adding each biomarker to the clinical model, which incorporated age, sex, complication of diabetes, medical admission, and serum creatinine.  $^{a}p < .05$  vs. clinical model